ARTICLE SUMMARY:
Despite evidence that LVADs and other cardiac assist devices can help the failing heart remodel and heal, they’re reserved for the sickest of patients because of the surgical and device-related risks and expense of current LVAD technology. Procyrion hopes to change that risk-benefit equation with a percutaneous circulatory assist pump for long-term use.
Heart pump company Procyrion Inc. got its start, as so many medical device companies do, because a physician was frustrated by the lack of therapeutic options for his patients.
